DiaMedica Therapeutics Inc.

DMAC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $15.6M $3.0M $4.5M $4.7M $4.7M $7.4M $3.9M $16.8M
Accounts Receivable $258.0K $236.0K $369.0K $82.0K $130.0K $340.0K $823.0K $780.0K
Inventory
Total Current Assets $60.6M $44.6M $53.7M $33.8M $45.4M $27.9M $8.8M $18.0M
Property, Plant & Equipment $145.0K $148.0K $131.0K $136.0K $70.0K $74.0K $64.0K $96.0K
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $61.4M $46.3M $54.2M $34.4M $45.6M $28.1M $9.1M $18.3M
Liabilities
Accounts Payable $1.5M $940.0K $926.0K $734.0K $509.0K $1.1M $182.0K $483.0K
Total Current Liabilities $5.1M $5.4M $2.8M $2.2M $1.5M $2.0M $1.3M $1.3M
Long-Term Debt
Total Liabilities $5.3M $5.6M $3.1M $2.6M $1.5M $2.1M $1.4M $1.3M
Stockholders' Equity
Retained Earnings $-172.8M $-140.0M $-115.6M $-96.2M $-82.5M $-68.9M $-56.6M $-46.0M
Total Stockholders' Equity $56.1M $40.7M $51.1M $31.8M $44.0M $26.0M $7.6M $17.0M
← Newer Page 1 of 2 Older →
Charlie Munger

If something is too hard, we move on to something else. What could be simpler than that?